

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 13, 2018

**Aquestive Therapeutics, Inc.**

(Exact name of Registrant as specified in its charter)

Delaware  
(State or Other Jurisdiction of Incorporation or  
Organization)

001-38599  
(Commission File Number)

82-3827296  
(I.R.S. Employer Identification No.)

30 Technology Drive  
Warren, NJ 07059  
(908) 941-1900  
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On August 13, 2018, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of current director Santo “Sandy” Costa as Chairman of the Company’s Board of Directors, effective as of August 8, 2018. Douglas Bratton, the Company’s outgoing Chairman of the Board of Directors, will continue to serve as a member of the Company’s Board of Directors.

A copy of the press release regarding the appointment of Mr. Costa as Chairman of the Board of Directors is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
<a href="#"><u>99.1</u></a>	Press Release, dated August 13, 2018

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2018

Aquestive Therapeutics, Inc.

By: /s/ John T. Maxwell

Name: John T. Maxwell

Title: Chief Financial Officer

---



### **Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors**

Warren, NJ, August 13, 2018 – Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that the Company’s Board of Directors confirmed its plan to appoint Santo “Sandy” Costa as Chairman, effective as of August 8<sup>th</sup>. Mr. Costa joined Aquestive’s Board in 2015 bringing over 40 years of experience in the pharmaceutical, healthcare and life sciences industries, as well as leadership in the legal sector. Douglas Bratton, Chairman since 2004, will continue to serve as a member of the Board of Directors.

“We would like to thank Doug for his leadership and invaluable guidance both as Chairman and Aquestive’s lead investor over the past 14 years. We are pleased that he will continue to serve as a director,” said Keith J. Kendall, Chief Executive Officer of Aquestive. “Sandy’s experience, expertise and insights from his work in the industry and on numerous other boards has made him an important part of the leadership of our company. We expect that to continue with Sandy in the role of Chairman.”

Mr. Costa stated, “Aquestive is uniquely positioned with a broad pipeline that spans late stage CNS candidates and earlier stage orally administered complex molecules. I look forward to continuing to work with the Board and the executive team as Aquestive transitions to a commercial organization in the coming months.”

Santo Costa joined Aquestive’s Board of Directors in 2015. Mr. Costa currently sits on the boards of Cytokinetics Inc. and Metabolon Inc. He has also served as a board member to numerous other public and private companies and charitable organizations. Mr. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, N.C. In addition to his legal practice, Mr. Costa’s experience includes President, Chief Operating Officer, and Vice Chairman of Quintiles Transnational Corp. where, during his tenure, he had responsibility for all operating divisions and worldwide business development. He is also a nationally recognized speaker on leadership and issues facing the pharmaceutical industry. Mr. Costa earned a B.S. in Pharmacy and his J.D. from St. John’s University.

#### **About Aquestive Therapeutics**

Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

#### **Media inquiries:**

Christopher Hippolyte  
[christopher.hippolyte@syneoshealth.com](mailto:christopher.hippolyte@syneoshealth.com)  
212-364-0458

#### **Investor inquiries:**

Stephanie Carrington  
[stephanie.carrington@icrinc.com](mailto:stephanie.carrington@icrinc.com)  
646-277-1282

---